Changes in the prevalence of COPD in Korea between 2001 and 2011 in the KNHANES data

Hong, Ji Young; Jung, Ji Ye; Lee, Myung Goo; Kim, Se Kyu; Chang, Joon; Lee, Chang Youl; Kim, Young Sam

doi:10.1016/j.rmed.2017.02.019

Cited by 14 publications

(15 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of COPD in China we report in our study (13·6% in 2014-15) is higher than the global estimate of the prevalence of COPD (11·7% in 2010). 23 Compared with other studies using the same diagnostic 24 and Japan (13·6% in 2005), 25 higher than the estimate from South Korea (12·4% in 2011), 26 and lower than estimates in three Latin American cities in the PLATINO study (São Paulo in Brazil, Santiago in Chile, and Montevideo in Uruguay [14·8-19·7%]). 18 The GOLD criteria we used in our study apply a fixed ratio of FEV 1 :FVC of less than 70% for a diagnosis of COPD.…”

Section: Discussionmentioning

confidence: 56%

Chronic obstructive pulmonary disease in China: a nationwide prevalence study

Fang

Gao

Bao

et al. 2018

The Lancet Respiratory Medicine

310

340

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 56%

Chronic obstructive pulmonary disease in China: a nationwide prevalence study

Fang

Gao

Bao

et al. 2018

The Lancet Respiratory Medicine

310

340

View full text Add to dashboard Cite

show abstract

“…We gathered data on adult patients with bronchiectasis (age ≥18) who were prescribed LAMA, LABA, or both between January 2008 and December 2018 at Asan Medical Center, a tertiary referral hospital in Seoul, Korea. We extracted data from patients diagnosed as bronchiectasis with CT scan and we excluded patients diagnosed with asthma or chronic obstructive pulmonary disease (COPD) who have been found to benefit from using long-acting bronchodilators (7); moreover, we excluded patients with a history of cigarette smoking, even 1 pack year, which is the most important cause of COPD in South Korea (8). We also performed a subgroup analysis by excluding patients who received concurrent treatment such as antibiotics, systemic steroids, or mucolytics, all of which affect lung function by improving mucociliary clearance and reducing chronic bronchial infection and inflammation (1,5).…”

Section: Study Design and Patientsmentioning

confidence: 99%

Effects of treatment with long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) on lung function improvement in patients with bronchiectasis: an observational study

Lee¹,

Lee²,

Lee³

et al. 2021

J Thorac Dis

View full text Add to dashboard Cite

Background: Patients with bronchiectasis are often treated with bronchodilators such as long-acting muscarinic antagonists (LAMA) or long-acting beta-agonists (LABA) for their symptoms, but empirical evidence supporting such practice is sparse. We evaluated the effect of LAMA and LABA on lung function improvement in patients with bronchiectasis. Methods: Using the in-house patient database at a tertiary referral hospital in Seoul, South Korea, we extracted data from patients diagnosed as bronchiectasis with computed tomography (CT) scan and treated with LAMA, LABA, or both. Patients with asthma, chronic obstructive pulmonary disease (COPD) or a history of cigarette smoking were excluded, and a subgroup analysis was performed in patients who did not receive concurrent treatments such as antibiotics, mucolytics or systemic steroids that may affect lung function improvement. Results: A total of 230 patients (males: 32.6%, median age: 60 years) were analyzed. Their mean forced expiratory volume in 1 second (FEV 1 ) was 53.3% of the predicted value [standard deviation (SD), 15.3]. The patients received LAMA (n=95), LABA (n=36), or both (LAMA-LABA; n=99), after which their FEV 1 values were increased by 0.102 liters (SD, 0.208; P<0.001), 0.133 liters (SD, 0.181; P<0.001), and 0.122 liters (SD, 0.230; P<0.001), respectively. In a subgroup of 97 patients who did not receive concurrent treatments, the FEV 1 was increased by with 0.107 liters (SD, 0.167; P<0.001), 0.165 liters (SD, 0.209; P=0.005), and 0.165 liters (SD, 0.187; P<0.001) in the LAMA, LABA, and LAMA-LABA groups, respectively. Baseline FEV 1 had a significant negative correlation with response to bronchodilator treatment in the total patient cohort (R=−0.242, P<0.001) and the subgroup of patients without concurrent treatments (R=−0.386, P<0.001). Conclusions:Treatment with bronchodilators such as LAMA or LABA was effective in improving lung function in patients with bronchiectasis, regardless of concurrent treatments that also improve lung function.These data may support the use of LAMA and LABA in patients with bronchiectasis.

show abstract

“…According to the Korean Health Insurance Review and Assessment Service database, the total cost of COPD-related medications in Korea rose 33.1% over 5 years [40]. Hong et al said that constant monitoring and prevention are needed because of the substantial socioeconomic burden of COPD [41]. Third, unlike previous studies that investigated the effects of only one type of beverage on COPD [4,8], this study considered three different beverages; soda, coffee, and green tea, simultaneously.…”

Section: Discussionmentioning

confidence: 99%

The Joint Effects of Some Beverages Intake and Smoking on Chronic Obstructive Pulmonary Disease in Korean Adults: Data Analysis of the Korea National Health and Nutrition Examination Survey (KNHANES), 2008–2015

Min

Huh

Moon

2020

IJERPH

View full text Add to dashboard Cite

Some beverages and smoking cause an inflammatory response in the lungs and airways in a similar way, ultimately affecting chronic obstructive pulmonary disease (COPD) occurrence. Using a nationally representative health survey database, this study investigates the individual and joint effects of consumption of different beverages and smoking on COPD. This study is a cross-sectional analysis of 15,961 Korean adults in the Korea National Health and Nutritional Examination Survey of 2008–2015. COPD was defined as forced expiratory volume in 1 s (FEV1) divided by forced vital capacity (FVC) <0.70. We used multiple linear and logistic regression models to examine the association of beverage consumption and smoking with an FEV1/FVC ratio and odds ratio (OR) for COPD. The mean FEV1/FVC ratio decreased with increasing soda intake (p = 0.016), coffee intake (p = 0.031), and smoking status; however, the mean FEV1/FVC ratio increased with increasing green tea intake frequency (p = 0.029). When soda intake increased to 10 times/month, the OR of having COPD increased to 1.04 times (95% CI: 1.01, 1.07). The positive joint effect of soda intake and smoking on COPD was marginally significant (p = 0.058). We found that soda intake, coffee intake, and smoking increased airflow limitation while green tea intake decreased it. In addition, soda intake and smoking had a positive joint effect on COPD in the Korean population.

show abstract

Changes in the prevalence of COPD in Korea between 2001 and 2011 in the KNHANES data

Abstract: We report a reduction in the age-standardized prevalence of COPD in Korea from 2001 to 2011. Continued surveillance and early prevention are required because the socioeconomic burden of COPD remains substantial.

Cited by 14 publications

References 25 publications

Chronic obstructive pulmonary disease in China: a nationwide prevalence study

Chronic obstructive pulmonary disease in China: a nationwide prevalence study

Effects of treatment with long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) on lung function improvement in patients with bronchiectasis: an observational study

The Joint Effects of Some Beverages Intake and Smoking on Chronic Obstructive Pulmonary Disease in Korean Adults: Data Analysis of the Korea National Health and Nutrition Examination Survey (KNHANES), 2008–2015

Contact Info

Product

Resources

About